A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.

@article{Tolcher2004API,
  title={A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.},
  author={Anthony William Tolcher and John J. Kuhn and Garry H. Schwartz and Amita Patnaik and Lisa A. Hammond and Ian Sherrard Thompson and Howard J. Fingert and David B Bushnell and Shazli Malik and Jeffrey I. Kreisberg and Elzbieta Izbicka and Leslie Smetzer and Eric Keith Rowinsky},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2004},
  volume={10 15},
  pages={
          5048-57
        }
}
PURPOSE To assess the feasibility of administering oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the Bcl-2 mRNA, with docetaxel to patients with hormone-refractory prostate cancer; to characterize the pertinent pharmacokinetic parameters, Bcl-2 protein inhibition in peripheral blood mononuclear cell(s) (PBMC) and tumor; and to seek preliminary evidence of antitumor activity. EXPERIMENTAL DESIGN Patients were treated with increasing doses of oblimersen sodium… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS, ESTIMATED 49% COVERAGE

55 Citations

0510'07'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 55 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

G3139 (Genasense) enhances docetaxel antitumor activity and leads to long-term survivors in the androgen-independent prostate cancer xenograph (PC3) model

  • AW Tolcher, S Roth, S Wynne
  • Clin Cancer Res
  • 2001
Highly Influential
5 Excerpts

cancer cells following androgen withdrawal therapy

  • M Vilenchik, AJ Raffo, L Benimetskaya
  • 2002

Similar Papers

Loading similar papers…